Krisztina Herédi‐Szabó

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

Joe Bentz, Michael O′Connor, Dallas Bednarczyk et al. · Drug Metabolism and Disposition · 2013 · 147 citations · Full text

Effect of Membrane Cholesterol on BSEP/Bsep Activity: Species Specificity Studies for Substrates and Inhibitors

Emese Kis, Enikő Ioja, Tünde Nagy et al. · Drug Metabolism and Disposition · 2009 · 94 citations

Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance

E. Kis, Tünde Nagy, Marghi Jani et al. · Annals of the Rheumatic Diseases · 2008 · 73 citations

Characterization of 5(6)-Carboxy-2,′7′-Dichlorofluorescein Transport by MRP2 and Utilization of this Substrate as a Fluorescent Surrogate for LTC4

Krisztina Herédi‐Szabó, Emese Kis, E. M. Molnar et al. · SLAS DISCOVERY · 2008 · 43 citations · Full text

Quantitative Systems Toxicology Analysis of<i>In Vitro</i>Mechanistic Assays Reveals Importance of Bile Acid Accumulation and Mitochondrial Dysfunction in TAK-875-Induced Liver Injury

Diane Longo, Jeffrey L. Woodhead, Paul Walker et al. · Toxicological Sciences · 2018 · 43 citations · Full text

Mitochondrial Dysfunction, Pathology, Cholangiopathies +23